These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 9973526

  • 21. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
    Mowat AM, Donachie AM, Jägewall S, Schön K, Löwenadler B, Dalsgaard K, Kaastrup P, Lycke N.
    J Immunol; 2001 Sep 15; 167(6):3398-405. PubMed ID: 11544331
    [Abstract] [Full Text] [Related]

  • 22. cAMP-independent effects of cholera toxin on B cell activation. III. Cholera toxin A subunit-mediated ADP-ribosylation acts synergistically with ionomycin or IL-4 to induce B cell proliferation.
    Francis ML, Okazaki I, Moss J, Kurosky A, Pecanha LM, Mond JJ.
    J Immunol; 1995 May 15; 154(10):4956-64. PubMed ID: 7730606
    [Abstract] [Full Text] [Related]

  • 23. Cyclic AMP-independent effects of cholera toxin on B cell activation. II. Binding of ganglioside GM1 induces B cell activation.
    Francis ML, Ryan J, Jobling MG, Holmes RK, Moss J, Mond JJ.
    J Immunol; 1992 Apr 01; 148(7):1999-2005. PubMed ID: 1312102
    [Abstract] [Full Text] [Related]

  • 24. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant.
    Yamamoto M, Kiyono H, Yamamoto S, Batanero E, Kweon MN, Otake S, Azuma M, Takeda Y, McGhee JR.
    J Immunol; 1999 Jun 15; 162(12):7015-21. PubMed ID: 10358143
    [Abstract] [Full Text] [Related]

  • 25. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS, Dietrich J, Agger EM, Lycke NY, Lövgren K, Andersen P.
    Infect Immun; 2007 Jan 15; 75(1):408-16. PubMed ID: 17074845
    [Abstract] [Full Text] [Related]

  • 26. The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability.
    Eriksson A, Lycke N.
    Vaccine; 2003 Dec 12; 22(2):185-93. PubMed ID: 14615145
    [Abstract] [Full Text] [Related]

  • 27. Targeted vaccine adjuvants based on modified cholera toxin.
    Lycke N.
    Curr Mol Med; 2005 Sep 12; 5(6):591-7. PubMed ID: 16178769
    [Abstract] [Full Text] [Related]

  • 28. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells.
    Helgeby A, Robson NC, Donachie AM, Beackock-Sharp H, Lövgren K, Schön K, Mowat A, Lycke NY.
    J Immunol; 2006 Mar 15; 176(6):3697-706. PubMed ID: 16517738
    [Abstract] [Full Text] [Related]

  • 29. The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses.
    Bagley K, Xu R, Ota-Setlik A, Egan M, Schwartz J, Fouts T.
    Hum Vaccin Immunother; 2015 Mar 15; 11(9):2228-40. PubMed ID: 26042527
    [Abstract] [Full Text] [Related]

  • 30. CTA1: Purified and display onto gram-positive enhancer matrix (GEM) particles as mucosal adjuvant.
    Zhang Y, Yu X, Hou L, Chen J, Li P, Qiao X, Zheng Q, Hou J.
    Protein Expr Purif; 2018 Jan 15; 141():19-24. PubMed ID: 28866467
    [Abstract] [Full Text] [Related]

  • 31. Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.
    Nedrud JG, Bagheri N, Schön K, Xin W, Bergroth H, Eliasson DG, Lycke NY.
    PLoS One; 2013 Jan 15; 8(12):e83321. PubMed ID: 24391754
    [Abstract] [Full Text] [Related]

  • 32. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity.
    Lycke N, Tsuji T, Holmgren J.
    Eur J Immunol; 1992 Sep 15; 22(9):2277-81. PubMed ID: 1381311
    [Abstract] [Full Text] [Related]

  • 33. Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain.
    Shim BS, Cheon IS, Lee E, Park SM, Choi Y, Jung DI, Yang E, Choi JA, Chun JY, Kim JO, Yun CH, Czerkinsky C, Song MK.
    J Immunol Res; 2018 Sep 15; 2018():9830701. PubMed ID: 29707588
    [Abstract] [Full Text] [Related]

  • 34. A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development.
    Bemark M, Bergqvist P, Stensson A, Holmberg A, Mattsson J, Lycke NY.
    J Immunol; 2011 Feb 01; 186(3):1399-410. PubMed ID: 21199899
    [Abstract] [Full Text] [Related]

  • 35. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.
    Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G.
    Infect Immun; 1997 Jul 01; 65(7):2821-8. PubMed ID: 9199455
    [Abstract] [Full Text] [Related]

  • 36. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice.
    Arêas AP, Oliveira ML, Miyaji EN, Leite LC, Aires KA, Dias WO, Ho PL.
    Biochem Biophys Res Commun; 2004 Aug 13; 321(1):192-6. PubMed ID: 15358234
    [Abstract] [Full Text] [Related]

  • 37. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity.
    Dickinson BL, Clements JD.
    Infect Immun; 1995 May 13; 63(5):1617-23. PubMed ID: 7729864
    [Abstract] [Full Text] [Related]

  • 38. Identification of motifs in cholera toxin A1 polypeptide that are required for its interaction with human ADP-ribosylation factor 6 in a bacterial two-hybrid system.
    Jobling MG, Holmes RK.
    Proc Natl Acad Sci U S A; 2000 Dec 19; 97(26):14662-7. PubMed ID: 11106366
    [Abstract] [Full Text] [Related]

  • 39. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins.
    Lycke N, Bemark M.
    Mucosal Immunol; 2010 Nov 19; 3(6):556-66. PubMed ID: 20844480
    [Abstract] [Full Text] [Related]

  • 40. Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cells.
    Schnitzler AC, Burke JM, Wetzler LM.
    Infect Immun; 2007 Jun 19; 75(6):3150-9. PubMed ID: 17353279
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.